Cargando…

Y-Site Physical Compatibility of Numeta G13E with Drugs Frequently Used at Neonatal Intensive Care

Preterm neonates require parenteral nutrition (PN) in addition to intravenous drug therapy. Due to limited venous access, drugs are often co-administered with PN via the same lumen. If incompatible, precipitation and emulsion destabilization may occur with the consequent risk of embolism and hyper-i...

Descripción completa

Detalles Bibliográficos
Autores principales: Nezvalova-Henriksen, Katerina, Nilsson, Niklas, Østerberg, Camilla Tomine, Staven Berge, Vigdis, Tho, Ingunn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408039/
https://www.ncbi.nlm.nih.gov/pubmed/32708409
http://dx.doi.org/10.3390/pharmaceutics12070677
_version_ 1783567745274609664
author Nezvalova-Henriksen, Katerina
Nilsson, Niklas
Østerberg, Camilla Tomine
Staven Berge, Vigdis
Tho, Ingunn
author_facet Nezvalova-Henriksen, Katerina
Nilsson, Niklas
Østerberg, Camilla Tomine
Staven Berge, Vigdis
Tho, Ingunn
author_sort Nezvalova-Henriksen, Katerina
collection PubMed
description Preterm neonates require parenteral nutrition (PN) in addition to intravenous drug therapy. Due to limited venous access, drugs are often co-administered with PN via the same lumen. If incompatible, precipitation and emulsion destabilization may occur with the consequent risk of embolism and hyper-immune reactions. Information on intravenous compatibility is scarce. Our aim was to analyse the compatibility of Numeta G13E with paracetamol, vancomycin and fentanyl because of the frequency of their use. A panel of methods was chosen to assess precipitation (sub-visual particle counting, turbidity measurement, Tyndall beam effect and pH measurement) and emulsion destabilization (mean droplet diameter measurement and sub-visual counting of oil droplets, followed by estimation of PFAT5 (percentage of fat residing in globules larger than 5 µm) and pH measurement). Samples in clinically relevant mixing ratios were tested immediately and after 4 h. All samples of drugs mixed with Numeta G13E were compared to unmixed controls. None of the tested drugs precipitated in contact with Numeta G13E, and we did not see any sign of emulsion destabilization when clinically relevant mixing ratios were applied. These results are reassuring. However, when contact time exceeds the established norm, caution in the form of filter utilisation and close inspection is advised.
format Online
Article
Text
id pubmed-7408039
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-74080392020-08-12 Y-Site Physical Compatibility of Numeta G13E with Drugs Frequently Used at Neonatal Intensive Care Nezvalova-Henriksen, Katerina Nilsson, Niklas Østerberg, Camilla Tomine Staven Berge, Vigdis Tho, Ingunn Pharmaceutics Article Preterm neonates require parenteral nutrition (PN) in addition to intravenous drug therapy. Due to limited venous access, drugs are often co-administered with PN via the same lumen. If incompatible, precipitation and emulsion destabilization may occur with the consequent risk of embolism and hyper-immune reactions. Information on intravenous compatibility is scarce. Our aim was to analyse the compatibility of Numeta G13E with paracetamol, vancomycin and fentanyl because of the frequency of their use. A panel of methods was chosen to assess precipitation (sub-visual particle counting, turbidity measurement, Tyndall beam effect and pH measurement) and emulsion destabilization (mean droplet diameter measurement and sub-visual counting of oil droplets, followed by estimation of PFAT5 (percentage of fat residing in globules larger than 5 µm) and pH measurement). Samples in clinically relevant mixing ratios were tested immediately and after 4 h. All samples of drugs mixed with Numeta G13E were compared to unmixed controls. None of the tested drugs precipitated in contact with Numeta G13E, and we did not see any sign of emulsion destabilization when clinically relevant mixing ratios were applied. These results are reassuring. However, when contact time exceeds the established norm, caution in the form of filter utilisation and close inspection is advised. MDPI 2020-07-18 /pmc/articles/PMC7408039/ /pubmed/32708409 http://dx.doi.org/10.3390/pharmaceutics12070677 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Nezvalova-Henriksen, Katerina
Nilsson, Niklas
Østerberg, Camilla Tomine
Staven Berge, Vigdis
Tho, Ingunn
Y-Site Physical Compatibility of Numeta G13E with Drugs Frequently Used at Neonatal Intensive Care
title Y-Site Physical Compatibility of Numeta G13E with Drugs Frequently Used at Neonatal Intensive Care
title_full Y-Site Physical Compatibility of Numeta G13E with Drugs Frequently Used at Neonatal Intensive Care
title_fullStr Y-Site Physical Compatibility of Numeta G13E with Drugs Frequently Used at Neonatal Intensive Care
title_full_unstemmed Y-Site Physical Compatibility of Numeta G13E with Drugs Frequently Used at Neonatal Intensive Care
title_short Y-Site Physical Compatibility of Numeta G13E with Drugs Frequently Used at Neonatal Intensive Care
title_sort y-site physical compatibility of numeta g13e with drugs frequently used at neonatal intensive care
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408039/
https://www.ncbi.nlm.nih.gov/pubmed/32708409
http://dx.doi.org/10.3390/pharmaceutics12070677
work_keys_str_mv AT nezvalovahenriksenkaterina ysitephysicalcompatibilityofnumetag13ewithdrugsfrequentlyusedatneonatalintensivecare
AT nilssonniklas ysitephysicalcompatibilityofnumetag13ewithdrugsfrequentlyusedatneonatalintensivecare
AT østerbergcamillatomine ysitephysicalcompatibilityofnumetag13ewithdrugsfrequentlyusedatneonatalintensivecare
AT stavenbergevigdis ysitephysicalcompatibilityofnumetag13ewithdrugsfrequentlyusedatneonatalintensivecare
AT thoingunn ysitephysicalcompatibilityofnumetag13ewithdrugsfrequentlyusedatneonatalintensivecare